Osteoarthritis (degenerative joint disease) is a common disorder that affects the working capability of both performance and pleasure horses. As you know, medical treatment of osteoarthritis was previously limited to symptomatic relief by use of steroids, analgesics, and non-steroidal anti-inflammatory drugs. More recently, equine practitioners have turned to structure-modifying osteoarthritis drugs in an attempt to hasten return to work and prevent or reduce the occurrence of osteoarthritis.
Pentosan polysulfate is one of these drugs, and is recognised as being chondroprotective. It has been shown to stimulate the synthesis of proteoglycans and hyaluronan as well as provide an anti-inflammatory effect. Despite the limited clinical research on the drug, many Australian clinicians use it as a therapy for idiopathic joint effusion, chronic degenerative joint disease, and prophylactically in performance horses prior to upcoming events.
The objective of this survey is to quantify the extent and approach of pentosan polysulfate use in Australia and its perceived effectiveness in treating and/or preventing osteoarthritis. All questions can be answered with a tick box or a numerical rank and will not take longer than 15-20 minutes of your time to complete.
Your participation in completing the survey is much appreciated and will help to define the clinical value of pentosan polysulfate in treating equine osteoarthritis. The results of this study will be circulated to all participants later this year. If you have any questions or comments, please feel free to contact Chelsea Kramer at the e-mail address below. Thank you for volunteering your time in this study.
University of Sydney
Faculty of Veterinary Science
BVSc, Year IV